Erica M. LaFata, Alyssa J. Moran, Nora D. Volkow, Ashley N. Gearhardt
{"title":"Now is the time to recognize and respond to addiction to ultra-processed foods","authors":"Erica M. LaFata, Alyssa J. Moran, Nora D. Volkow, Ashley N. Gearhardt","doi":"10.1038/s41591-025-03858-6","DOIUrl":null,"url":null,"abstract":"<p>The idea that certain ultra-processed foods — such as candy, cookies, and chips — can be addictive is receiving increasing attention in the USA and elsewhere. During the past two years, Congressional hearings have addressed the role of addictive ultra-processed foods in escalating rates of childhood chronic diseases. In December 2024, a lawsuit was filed in Philadelphia, accusing 11 ultra-processed-food companies of designing addictive food products and aggressively marketing them toward children.</p><p>Reflecting the growing consensus that addiction science could inform food policy, the US Food and Drug Administration (FDA) and National Institutes of Health (NIH) have announced a new initiative modeled on the successful Tobacco Regulatory Science Program, which will unite both agencies’ expertise to “transform nutrition and food-related research”. That certain foods can trigger addictive behavior consistent with substance-use disorders (SUDs) is accepted by many addiction scientists and supported by evidence of neurobiological overlap with the brain circuits and molecular targets implicated in ‘classical’ drug addictions<sup>1</sup>. Yet addiction to ultra-processed food is not formally recognized by medical classification systems, including the Diagnostic and Statistical Manual of Mental Disorders (DSM)<sup>2</sup> and the International Classification of Diseases (ICD). This is an oversight with major consequences for public health.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"29 1","pages":""},"PeriodicalIF":58.7000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-025-03858-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The idea that certain ultra-processed foods — such as candy, cookies, and chips — can be addictive is receiving increasing attention in the USA and elsewhere. During the past two years, Congressional hearings have addressed the role of addictive ultra-processed foods in escalating rates of childhood chronic diseases. In December 2024, a lawsuit was filed in Philadelphia, accusing 11 ultra-processed-food companies of designing addictive food products and aggressively marketing them toward children.
Reflecting the growing consensus that addiction science could inform food policy, the US Food and Drug Administration (FDA) and National Institutes of Health (NIH) have announced a new initiative modeled on the successful Tobacco Regulatory Science Program, which will unite both agencies’ expertise to “transform nutrition and food-related research”. That certain foods can trigger addictive behavior consistent with substance-use disorders (SUDs) is accepted by many addiction scientists and supported by evidence of neurobiological overlap with the brain circuits and molecular targets implicated in ‘classical’ drug addictions1. Yet addiction to ultra-processed food is not formally recognized by medical classification systems, including the Diagnostic and Statistical Manual of Mental Disorders (DSM)2 and the International Classification of Diseases (ICD). This is an oversight with major consequences for public health.
期刊介绍:
Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors.
Nature Medicine consider all types of clinical research, including:
-Case-reports and small case series
-Clinical trials, whether phase 1, 2, 3 or 4
-Observational studies
-Meta-analyses
-Biomarker studies
-Public and global health studies
Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.